This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Taisho Pharmaceutical Holdings Yönetim

Yönetim kriter kontrolleri 3/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Akira Uehara

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	10.8yrs
CEO sahipliği	n/a
Yönetim ortalama görev süresi	9.8yrs
Yönetim Kurulu ortalama görev süresi	5.3yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Akira Uehara'un ücretlendirmesi Taisho Pharmaceutical Holdings'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Dec 31 2023	n/a	n/a	JP¥8b
Sep 30 2023	n/a	n/a	JP¥16b
Jun 30 2023	n/a	n/a	JP¥18b
Mar 31 2023	n/a	n/a	JP¥19b
Dec 31 2022	n/a	n/a	JP¥25b
Sep 30 2022	n/a	n/a	JP¥21b
Jun 30 2022	n/a	n/a	JP¥18b
Mar 31 2022	JP¥113m	JP¥102m	JP¥13b
Dec 31 2021	n/a	n/a	JP¥8b
Sep 30 2021	n/a	n/a	JP¥5b
Jun 30 2021	n/a	n/a	JP¥8b
Mar 31 2021	JP¥119m	JP¥100m	JP¥13b
Dec 31 2020	n/a	n/a	JP¥17b
Sep 30 2020	n/a	n/a	JP¥17b
Jun 30 2020	n/a	n/a	JP¥16b
Mar 31 2020	JP¥111m	JP¥97m	JP¥21b
Dec 31 2019	n/a	n/a	JP¥15b
Sep 30 2019	n/a	n/a	JP¥21b
Jun 30 2019	n/a	n/a	JP¥46b
Mar 31 2019	JP¥116m	JP¥94m	JP¥49b

Tazminat ve Piyasa: Akira şirketinin toplam tazminatının JP pazarındaki benzer büyüklükteki şirketlerle karşılaştırıldığında makul olup olmadığını tespit etmek için yeterli veri yok.

Tazminat ve Kazançlar: Akira 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Akira Uehara (82 yo)

10.8yrs

Görev süresi

JP¥113,000,000

Tazminat

Mr. Akira Uehara has been the Chief Executive Officer at Taisho Pharmaceutical Holdings Co., Ltd since July2013. Mr. Uehara served as Chairman of Taisho Pharmaceutical Co., Ltd until December 30, 2015 and...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Akira Uehara	CEO & Representative Director	10.8yrs	JP¥113.00m	Veri yok
Shigeru Uehara	Executive VP & Director	8.8yrs	JP¥123.00m	0% ¥ 0
Shinichi Tanaka	General Manager of Corporate Communications	no data	Veri yok	Veri yok
Ken Uehara	MD & Executive Director	12.5yrs	JP¥105.00m	0% ¥ 0
Tetsu Watanabe	Executive Director	no data	Veri yok	0% ¥ 0
Jun Kuroda	Executive VP & Director	2.8yrs	Veri yok	0% ¥ 0

9.8yrs

Ortalama Görev Süresi

Deneyimli Yönetim: 4581 'un yönetim ekibi deneyimli ve deneyimlidir ( 9.8 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Akira Uehara	CEO & Representative Director	no data	JP¥113.00m	Veri yok
Shigeru Uehara	Executive VP & Director	16.8yrs	JP¥123.00m	0% ¥ 0
Ken Uehara	MD & Executive Director	10.8yrs	JP¥105.00m	0% ¥ 0
Tetsu Watanabe	Executive Director	8.8yrs	Veri yok	0% ¥ 0
Jun Kuroda	Executive VP & Director	2.8yrs	Veri yok	0% ¥ 0
Makoto Matsuo	Audit & Supervisory Board Member	3.8yrs	Veri yok	0% ¥ 0
Kazuya Kameo	Audit & Supervisory Board Member	5.3yrs	Veri yok	0% ¥ 0
Chushiro Aoi	Outside Audit & Supervisory Board Member	8.8yrs	Veri yok	Veri yok
Takeshi Kunibe	Independent Outside Director	5.3yrs	Veri yok	0% ¥ 0
Osamu Kitatani	Director	3.3yrs	Veri yok	0% ¥ 0
Takeshi Ikoma	Audit & Supervisory Board Member	2.8yrs	Veri yok	0% ¥ 0

5.3yrs

Ortalama Görev Süresi

74yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 4581 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 5.3 yıldır).

This company listing is no longer active

Taisho Pharmaceutical Holdings Yönetim

Yönetim kriter kontrolleri 3/4

Anahtar bilgiler

Son yönetim güncellemeleri

Taisho Pharmaceutical Holdings Co., Ltd., Annual General Meeting, Jun 29, 2023

Less than half of directors are independent

Taisho Pharmaceutical Holdings Co., Ltd., Annual General Meeting, Jun 29, 2022

Less than half of directors are independent

Recent updates

Taisho Pharmaceutical Holdings Co., Ltd.(TSE:4581) dropped from FTSE All-World Index (USD)

Taisho Pharmaceutical Holdings Co., Ltd.(TSE:4581) dropped from S&P Japan 500

Taisho Pharmaceutical Holdings Co., Ltd. to Delist from Standard Section of Tokyo Stock Exchange, Effective April 09, 2024

Oasis Management Send a Notice to Taisho Pharmaceutical Holdings Co., Ltd

Third quarter 2024 earnings: Revenues and EPS in line with analyst expectations

Consensus EPS estimates fall by 29%

Price target increased by 8.2% to JP¥6,180

Otemon Co., Ltd. completed the acquisition of 73.12% stake in Taisho Pharmaceutical Holdings Co., Ltd. (TSE:4581) for approximately ¥520 billion.

Taisho Pharmaceutical Holdings Co., Ltd. to Report Q3, 2024 Results on Feb 13, 2024

New minor risk - Share price stability

Investor sentiment improves as stock rises 18%

Consensus EPS estimates increase by 11%

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

New major risk - Revenue and earnings growth

Price target increased by 7.9% to JP¥5,710

Taisho Pharmaceutical Holdings Co., Ltd. to Report Q2, 2024 Results on Nov 10, 2023

Upcoming dividend of JP¥50.00 per share at 1.6% yield

Now 22% undervalued

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Taisho Pharmaceutical Holdings Co., Ltd. to Report Q1, 2024 Results on Aug 04, 2023

Now 20% undervalued after recent price drop

Full year 2023 earnings: EPS misses analyst expectations

Taisho Pharmaceutical Holdings Co., Ltd., Annual General Meeting, Jun 29, 2023

Consensus EPS estimates increase by 17%

Upcoming dividend of JP¥50.00 per share at 1.8% yield

Now 21% undervalued after recent price drop

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Consensus EPS estimates increase by 14%

Taisho Pharmaceutical Holdings Co., Ltd. to Report Q3, 2023 Results on Feb 09, 2023

Less than half of directors are independent

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Upcoming dividend of JP¥50.00 per share

Taisho Pharmaceutical Holdings Co., Ltd. to Report Q2, 2023 Results on Nov 10, 2022

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Price target decreased to JP¥5,073

Taisho Pharmaceutical Holdings Co., Ltd. to Report Q1, 2023 Results on Aug 03, 2022

Consensus EPS estimates fall by 12%

Taisho Pharmaceutical Holdings Co., Ltd., Annual General Meeting, Jun 29, 2022

Full year 2022 earnings: EPS in line with expectations, revenues disappoint

Less than half of directors are independent

Taisho Pharmaceutical Holdings Co., Ltd. to Report Fiscal Year 2022 Results on May 13, 2022

Upcoming dividend of JP¥50.00 per share

Taisho Pharmaceutical Holdings Co., Ltd. Revises Earnings Guidance for the Ending March 31, 2022

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Consensus forecasts updated

Second quarter 2022 earnings released: EPS JP¥21.09 (vs JP¥65.53 in 2Q 2021)

Upcoming dividend of JP¥50.00 per share

First quarter 2022 earnings released: EPS JP¥14.77 (vs JP¥75.98 in 1Q 2021)

Full year 2021 earnings released: EPS JP¥167 (vs JP¥257 in FY 2020)

Taisho Pharmaceutical Holdings Co., Ltd. (TSE:4581) executed a share exchange agreement to acquire remaining 37% stake in Biofermin Pharmaceutical Co., Ltd. (TSE:4517) from a group of sellers for ¥14.8 billion.

Upcoming dividend of JP¥50.00 per share

New 90-day high: JP¥7,330

Taisho Pharmaceutical Holdings Co., Ltd. to Report Fiscal Year 2021 Results on May 14, 2021

Third quarter 2021 earnings released: EPS JP¥36.85 (vs JP¥36.96 in 3Q 2020)

Revenue and earnings miss expectations

New 90-day high: JP¥7,030

Taisho Pharmaceutical Holdings Co., Ltd. to Report Q3, 2021 Results on Feb 04, 2021

Insilico Medicine Partners with Taisho Pharmaceutical Co., Ltd. on End-To-End Ai-Powered Senolytic Drug Discovery

Taisho Pharmaceutical Holdings Co., Ltd. to Report Q2, 2021 Results on Oct 29, 2020

CEO Tazminat Analizi

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş